BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board


3/23/2009 12:01:57 PM

BOULDER, Colo., March 23 /PRNewswire/ -- N30 Pharma (N30) today announced that Joseph Loscalzo, M.D., PhD., has joined the Board of Directors of the Company.

Dr. Loscalzo currently serves as Hersey Professor of the Theory and Practice of Medicine at Harvard, Physician-in-Chief at Brigham and Women's Hospital, Editor-in-Chief of Circulation, and has recently joined the senior editorial Board of Harrison's Principles of Internal Medicine. Dr. Loscalzo has longstanding research interests in cardiovascular medicine, nitric oxide and redox biology with over 500 scientific publications and authoring or editing of 24 books.

"I am pleased to join the Board of N30 at an exciting time for the company. N30 is developing compounds of substantial potential importance that offer a unique means for modulating endogenous NO in the cardiovascular and pulmonary systems, and I look forward to helping the Board in managing the future of the Company," Dr. Loscalzo commented.

Dr. Loscalzo will also Chair the company's Scientific Advisory Board. The N30 SAB will provide the company with world-class thinking on the key biological, biochemical, translational, and clinical issues associated with developing important new classes of therapeutics in cardiopulmonary medicine.

Dr. Charles Scoggin, CEO of N30, commented on the expansion of the Board. "We are thrilled that a world-class clinical and scientific mind like Dr. Loscalzo shares our excitement over the great clinical potential in N30 Pharma, and we will look forward to working closely with him as we move the company forward."

About N30 Pharma

N30 Pharma is a cardiopulmonary medicine company focused on the modulation of endogenous Nitric Oxide bioavailability using targeted novel small molecule drugs. The company is headquartered in Boulder, Colorado and New York City, NY.

CONTACT: N30 Pharma, +1-720-945-7700, info@N30pharma.com

Web site: http://www.n30pharma.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES